论文部分内容阅读
为研究ＣＤＫ４Ⅰ／Ｐ１６与非小细胞肺癌的发生及发展的关系，应用免疫组化ＬＳＡＢ法研究了８３例肺癌手术标本中ＣＤＫ４Ⅰ蛋白的表达。结果显示，ＣＤＫ４Ⅰ蛋白表达总的平均阳性率为６５．９３％。Ｐ１６蛋白表达与肺癌的临床分期，组织学分类、肺癌原发部位、患者的年龄及有淋巴结转移的原发灶与无淋巴结转移的原发灶之间比较无显著差异（Ｐ＞０．０５），中一高分化的肺癌（７７．９５％）与低分化的肺癌（５３．０５％）之间有显著差异（Ｐ＜０．０１）；肺癌的原发灶（６４．１６％）与相应转移灶（淋巴灶）（５３．６６％）之间有显著差异（Ｐ＜０．０１）。肿瘤大小Ｔ１＋Ｔ２（６８．９０％）与Ｔ３＋Ｔ４（６０．８３％）之间差异显著（Ｐ＜０．０５）。本研究结果表明ＣＤＫ４Ⅰ蛋白检测可以作为人非小细胞肺癌的抑制基因，并可能是肺癌术后预后的重要指标之一。
To study the relationship between CDK4I/P16 and the occurrence and development of non-small cell lung cancer, the expression of CDK4I protein in 83 surgical specimens of lung cancer was studied by immunohistochemical LSAB method. The results showed that the overall average positive rate of CDK4I protein expression was 65.93%. There was no significant difference between the expression of P16 protein and the clinical stage, histological classification, primary site of lung cancer, age of patients with primary lung cancer, primary tumor with lymph node metastasis, and primary tumor without lymph node metastasis (P>0.05). There was a significant difference between moderately well-differentiated lung cancer (77.95%) and poorly differentiated lung cancer (53.05%) (P<0.01); primary lung cancer (64.16%) and corresponding There was a significant difference between the metastatic foci (lymphatic foci) (53.66%) (P<0.01). There was a significant difference between tumor size T1+T2 (68.90%) and T3+T4 (60.83%) (P<0.05). The results of this study indicate that CDK4I protein detection can be used as an inhibitor of human non-small cell lung cancer and may be one of the important indicators of postoperative prognosis of lung cancer.